Browse CCL7

Summary
SymbolCCL7
Namechemokine (C-C motif) ligand 7
Aliases MCP-3; NC28; FIC; MARC; MCP3; monocyte chemoattractant protein 3; monocyte chemotactic protein 3; SCYA6; SCY ......
Chromosomal Location17q11.2-q12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Secreted.
Domain PF00048 Small cytokines (intecrine/chemokine)
Function

Chemotactic factor that attracts monocytes and eosinophils, but not neutrophils. Augments monocyte anti-tumor activity. Also induces the release of gelatinase B. This protein can bind heparin. Binds to CCR1, CCR2 and CCR3.

> Gene Ontology
 
Biological Process GO:0002548 monocyte chemotaxis
GO:0002685 regulation of leukocyte migration
GO:0002687 positive regulation of leukocyte migration
GO:0002688 regulation of leukocyte chemotaxis
GO:0002690 positive regulation of leukocyte chemotaxis
GO:0006874 cellular calcium ion homeostasis
GO:0006875 cellular metal ion homeostasis
GO:0008360 regulation of cell shape
GO:0009314 response to radiation
GO:0010212 response to ionizing radiation
GO:0010332 response to gamma radiation
GO:0022604 regulation of cell morphogenesis
GO:0030335 positive regulation of cell migration
GO:0030593 neutrophil chemotaxis
GO:0030595 leukocyte chemotaxis
GO:0031349 positive regulation of defense response
GO:0032103 positive regulation of response to external stimulus
GO:0034341 response to interferon-gamma
GO:0034612 response to tumor necrosis factor
GO:0035747 natural killer cell chemotaxis
GO:0040017 positive regulation of locomotion
GO:0043410 positive regulation of MAPK cascade
GO:0045471 response to ethanol
GO:0048245 eosinophil chemotaxis
GO:0048247 lymphocyte chemotaxis
GO:0050727 regulation of inflammatory response
GO:0050729 positive regulation of inflammatory response
GO:0050900 leukocyte migration
GO:0050920 regulation of chemotaxis
GO:0050921 positive regulation of chemotaxis
GO:0051272 positive regulation of cellular component movement
GO:0055074 calcium ion homeostasis
GO:0060326 cell chemotaxis
GO:0070098 chemokine-mediated signaling pathway
GO:0070371 ERK1 and ERK2 cascade
GO:0070372 regulation of ERK1 and ERK2 cascade
GO:0070374 positive regulation of ERK1 and ERK2 cascade
GO:0070555 response to interleukin-1
GO:0071346 cellular response to interferon-gamma
GO:0071347 cellular response to interleukin-1
GO:0071356 cellular response to tumor necrosis factor
GO:0071361 cellular response to ethanol
GO:0071621 granulocyte chemotaxis
GO:0071674 mononuclear cell migration
GO:0072503 cellular divalent inorganic cation homeostasis
GO:0072507 divalent inorganic cation homeostasis
GO:0072676 lymphocyte migration
GO:0072677 eosinophil migration
GO:0097305 response to alcohol
GO:0097306 cellular response to alcohol
GO:0097529 myeloid leukocyte migration
GO:0097530 granulocyte migration
GO:1901623 regulation of lymphocyte chemotaxis
GO:1990266 neutrophil migration
GO:2000147 positive regulation of cell motility
GO:2000401 regulation of lymphocyte migration
GO:2000403 positive regulation of lymphocyte migration
GO:2000501 regulation of natural killer cell chemotaxis
GO:2000503 positive regulation of natural killer cell chemotaxis
Molecular Function GO:0001664 G-protein coupled receptor binding
GO:0005125 cytokine activity
GO:0005126 cytokine receptor binding
GO:0005539 glycosaminoglycan binding
GO:0008009 chemokine activity
GO:0008201 heparin binding
GO:0031726 CCR1 chemokine receptor binding
GO:0031727 CCR2 chemokine receptor binding
GO:0042379 chemokine receptor binding
GO:0048020 CCR chemokine receptor binding
GO:1901681 sulfur compound binding
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG hsa04060 Cytokine-cytokine receptor interaction
hsa04062 Chemokine signaling pathway
Reactome -
Summary
SymbolCCL7
Namechemokine (C-C motif) ligand 7
Aliases MCP-3; NC28; FIC; MARC; MCP3; monocyte chemoattractant protein 3; monocyte chemotactic protein 3; SCYA6; SCY ......
Chromosomal Location17q11.2-q12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between CCL7 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between CCL7 and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
29651051colon carcinomaInhibit immunitySubsequent functional analyses implicated both MEK/ERK and PI3K signaling upstream of CCL7 upregulation and identified CCL7 (but not CCL5) as a critical migration/invasion factor, acting via the chemokine receptor CCR3.
Summary
SymbolCCL7
Namechemokine (C-C motif) ligand 7
Aliases MCP-3; NC28; FIC; MARC; MCP3; monocyte chemoattractant protein 3; monocyte chemotactic protein 3; SCYA6; SCY ......
Chromosomal Location17q11.2-q12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of CCL7 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolCCL7
Namechemokine (C-C motif) ligand 7
Aliases MCP-3; NC28; FIC; MARC; MCP3; monocyte chemoattractant protein 3; monocyte chemotactic protein 3; SCYA6; SCY ......
Chromosomal Location17q11.2-q12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of CCL7 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.8250.0596
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-1.260.0795
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.4930.418
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-1.0680.293
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.70.674
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-1.5130.37
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.3460.661
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.0660.956
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.7940.552
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.1070.903
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 28-0.4060.719
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.1830.529
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of CCL7 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.703.70.27
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.703.70.314
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolCCL7
Namechemokine (C-C motif) ligand 7
Aliases MCP-3; NC28; FIC; MARC; MCP3; monocyte chemoattractant protein 3; monocyte chemotactic protein 3; SCYA6; SCY ......
Chromosomal Location17q11.2-q12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of CCL7. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolCCL7
Namechemokine (C-C motif) ligand 7
Aliases MCP-3; NC28; FIC; MARC; MCP3; monocyte chemoattractant protein 3; monocyte chemotactic protein 3; SCYA6; SCY ......
Chromosomal Location17q11.2-q12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of CCL7. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by CCL7.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolCCL7
Namechemokine (C-C motif) ligand 7
Aliases MCP-3; NC28; FIC; MARC; MCP3; monocyte chemoattractant protein 3; monocyte chemotactic protein 3; SCYA6; SCY ......
Chromosomal Location17q11.2-q12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of CCL7. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolCCL7
Namechemokine (C-C motif) ligand 7
Aliases MCP-3; NC28; FIC; MARC; MCP3; monocyte chemoattractant protein 3; monocyte chemotactic protein 3; SCYA6; SCY ......
Chromosomal Location17q11.2-q12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of CCL7 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolCCL7
Namechemokine (C-C motif) ligand 7
Aliases MCP-3; NC28; FIC; MARC; MCP3; monocyte chemoattractant protein 3; monocyte chemotactic protein 3; SCYA6; SCY ......
Chromosomal Location17q11.2-q12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between CCL7 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolCCL7
Namechemokine (C-C motif) ligand 7
Aliases MCP-3; NC28; FIC; MARC; MCP3; monocyte chemoattractant protein 3; monocyte chemotactic protein 3; SCYA6; SCY ......
Chromosomal Location17q11.2-q12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting CCL7 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.